Therapy Response Correlation with Tumor Radio-Sensitivity for Non-Hodgkin's Lymphoma Treated with 131I Tositumomab

被引：0
|
作者：
Roberson, P. L. [1 ]
Wilderman, S. J. [1 ]
Avram, A. M. [1 ]
Kaminski, M. S. [1 ]
Schipper, M. J. [1 ]
Dewaraja, Y. K. [1 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2012年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P0125
引用
收藏
页码：S336 / S336
页数：1
相关论文
共 50 条
  • [1] Tositumomab and 131I therapy in non-Hodgkin's lymphoma
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 2005, 46 : 128S - 140S
  • [2] Safety and Efficacy of I(131) Tositumomab in the Treatment of non-Hodgkin's Lymphoma
    Illidge, Tim
    Ivanov, Andrei
    Du, Yong
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 621 - 631
  • [3] Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma
    Dosik, AD
    Coleman, M
    Kostakoglu, L
    Furman, RR
    Fiore, JM
    Muss, D
    Niesvizky, R
    Shore, T
    Schuster, MW
    Stewart, P
    Vallabhajosula, S
    Goldsmith, SJ
    Leonard, JP
    CANCER, 2006, 106 (03) : 616 - 622
  • [4] Tumor response predictors in radioimmunotherapy of previously untreated non-Hodgkin's lymphoma (NHL) with Iodine I 131 tositumomab.
    Zasadny, KR
    Rommelfanger, SG
    Regan, DD
    McCullough, NT
    Kroll, S
    Stagg, R
    Kaminski, MS
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 29P - 30P
  • [5] Prediction of response to 131I Tositumomab therapy using 18F-fluorodeoxyglucose positron emission tomography in patients with non-Hodgkin's lymphoma.
    Kostakoglu, L
    Leonard, JP
    Coleman, M
    Zoe, H
    Vallabhajosula, S
    Fiore, JM
    Dreher, D
    Goldsmith, J
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 119P - 119P
  • [6] Patient-specific characteristics correlate with the effective half-life of 131I tositumomab therapy in non-Hodgkin's lymphoma (NHL).
    Kostakoglu, L
    Leonard, JP
    Coleman, M
    Kroll, SM
    Bhatnagar, A
    Vallabhajosula, S
    Magnuson, D
    Goldsmith, SJ
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 79P - 79P
  • [7] Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma
    Davies, AJ
    Rohatiner, AZS
    Howell, S
    Britton, KE
    Owens, SE
    Micallef, IN
    Deakin, DP
    Carrington, BM
    Lawrance, JA
    Vinnicombe, S
    Mather, SJ
    Clayton, J
    Foley, R
    Jan, H
    Kroll, S
    Harris, M
    Amess, J
    Norton, AJ
    Lister, TA
    Radford, JA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) : 1469 - 1479
  • [8] Methodology to Incorporate the BED and EUD in PatientSpecific 3-Dimensional Dosimetry for Non-Hodgkin's Lymphoma Patients Targeted with 131I Tositumomab Therapy
    Amro, H.
    Wilderman, S.
    Dewaraja, Y.
    Roberson, P.
    MEDICAL PHYSICS, 2009, 36 (06)
  • [9] 131I-Tositumomab (Bexxar®) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma: Clinical Experience
    Iagaru, A.
    Knox, S.
    Goris, M. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S148 - S149
  • [10] Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab
    Kaminski, MS
    Radford, JA
    Gregory, SA
    Leonard, JP
    Knox, SJ
    Kroll, S
    Wahl, RL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) : 7985 - 7993
12345